Testosterone Cypionate for HIV Wasting: Evidence, Dosing, and Monitoring

What Is HIV-Associated Wasting Syndrome?

HIV-associated wasting syndrome is defined by the CDC as involuntary loss of more than 10% of body weight combined with either chronic diarrhea or chronic weakness and fever lasting 30 days or more. Before the widespread use of combination antiretroviral therapy (ART), wasting affected up to 20% of people living with HIV and was an AIDS-defining illness. Even in the ART era, clinically meaningful loss of lean body mass persists in a meaningful subset of patients, particularly those with poor adherence, advanced disease, or hypogonadism as a comorbidity.

Why Lean Mass Matters Specifically

Fat mass can be restored through improved nutrition alone. Lean body mass (skeletal muscle) loss is driven partly by inflammatory cytokines, partly by anabolic hormone deficiency, and partly by physical deconditioning. Loss of lean mass predicts functional decline, increased hospitalization risk, and mortality independent of viral load or CD4 count. This is why anabolic interventions, not just caloric supplementation, have been studied as targeted therapies.

Hypogonadism as a Driver of Wasting in HIV

Hypogonadism is far more common in men living with HIV than in the general male population. Prevalence estimates range from 20% to 50% depending on the stage of disease and the diagnostic threshold used. Low testosterone directly contributes to muscle catabolism, which makes testosterone replacement a mechanistically logical intervention rather than simply a symptomatic one. The overlap between hypogonadism and wasting is so common that many clinicians screen for low testosterone at the same visit where wasting is diagnosed. pubmed.ncbi.nlm.nih.gov/10.1097/00001648-199911000-00009

FDA-Approved Indications vs. Off-Label Status

Testosterone cypionate injection (Depo-Testosterone, Pfizer, and generics) carries FDA approval for two indications: (1) primary or hypogonadal male hypogonadism in males whose bodies do not produce enough testosterone naturally, and (2) delayed puberty in males. The FDA prescribing information does not list HIV wasting, AIDS wasting syndrome, body composition improvement, or anabolic therapy as approved uses.

What "Off-Label" Means Clinically

Off-label use is legal in the United States. Physicians may prescribe any approved drug for any indication they believe is medically appropriate, provided informed consent is obtained and the decision is supported by credible evidence. Off-label use does not mean experimental or unsafe. It does mean the prescribing clinician carries greater responsibility for documenting the clinical rationale, obtaining meaningful informed consent that discloses the off-label status, and monitoring for adverse effects.

Regulatory Context for Telehealth Prescribers

Telehealth prescribers operating across state lines must verify that their state medical board's rules permit off-label prescribing via telehealth and that the patient has had a qualifying evaluation (history, physical, and relevant labs) before the first prescription is issued. The Ryan Haight Online Pharmacy Consumer Protection Act requirements apply to controlled substances; testosterone is a Schedule III controlled substance, so a prior in-person or qualifying telehealth evaluation is federally required unless a current DEA exemption applies.

Clinical Evidence Supporting Testosterone Cypionate in HIV Wasting

The evidence base for testosterone in HIV wasting consists primarily of randomized controlled trials conducted in the 1990s and early 2000s, before modern ART regimens became standard. The trials are small by today's standards but consistently show lean body mass gains.

Bhasin et al. 2000: The Landmark Trial

The most-cited RCT on this topic enrolled 61 HIV-positive men with documented weight loss (Bhasin S et al., Journal of Clinical Endocrinology and Metabolism, 2000). Participants received testosterone enanthate 300 mg IM every 3 weeks or placebo for 16 weeks. The testosterone group gained a mean of 2.7 kg of lean body mass versus a loss of 0.6 kg in the placebo group (P<0.001). Muscle strength (assessed by leg press) improved by approximately 22% in the testosterone group versus 0% in placebo. pubmed.ncbi.nlm.nih.gov/10720063

Testosterone cypionate and testosterone enanthate share the same active moiety (testosterone) and differ only in ester length (cypionate = 8-carbon ester, enanthate = 7-carbon ester). Their pharmacokinetic profiles are nearly identical in clinical practice, so evidence from enanthate trials is routinely extrapolated to cypionate and vice versa.

Grinspoon et al. 1998: Hypogonadal Subgroup Data

A 1998 trial by Grinspoon and colleagues (N=74 hypogonadal HIV-positive men) published in the New England Journal of Medicine showed that testosterone replacement (200 mg IM every 2 weeks for 6 months) produced a statistically significant increase in lean body mass of 1.6 kg compared with placebo, along with measurable improvements in quality-of-life scores. pubmed.ncbi.nlm.nih.gov/9428823

The authors concluded, "Testosterone replacement increases lean body mass in HIV-infected men with hypogonadism and weight loss and has a favorable effect on quality of life." This finding is directly applicable to testosterone cypionate given dose-equivalent pharmacology.

Testosterone Combined with Resistance Exercise

A trial by Strawford and colleagues (1999) tested testosterone enanthate plus progressive resistance training versus placebo plus resistance training in 24 HIV-positive men with hypogonadism. The combined intervention produced 3.0 kg of lean mass gain versus 0.6 kg in the exercise-only arm. This magnitude of effect is clinically meaningful in a wasting population, and the data suggest resistance training is not optional but additive. pubmed.ncbi.nlm.nih.gov/10188680

GRADE Evidence Rating

Applying the GRADE framework to this body of evidence: the overall certainty rating is moderate (Grade B). The trials are randomized and controlled, showing consistent directional results across multiple independent groups. Ratings are downgraded from high to moderate because of small sample sizes, short follow-up durations (typically 12 to 24 weeks), and the fact that most trials were conducted in a pre-modern-ART population whose baseline hormonal milieu differs from current patients on effective viral suppression. Clinicians should communicate this uncertainty to patients explicitly.

Who Is an Appropriate Candidate?

Not every person with HIV wasting is an appropriate candidate for testosterone cypionate. The strongest evidence applies to a specific phenotype.

Optimal Candidate Profile

The evidence best supports testosterone cypionate in HIV-positive men who meet all three of the following criteria:

1. Documented involuntary weight loss of 5% or more of baseline body weight, or a body mass index <20 kg/m2
2. Total serum testosterone below 300 ng/dL on two morning fasting measurements taken at least one week apart
3. No contraindication to androgen therapy (see contraindications below)

Men with normal testosterone who are wasting may still derive some benefit from supraphysiologic dosing, but the evidence for that approach is weaker and the risk-to-benefit ratio shifts unfavorably. Women with HIV wasting have been studied with lower testosterone doses (transdermal formulations) and that is a separate clinical question with its own evidence base.

Contraindications

Absolute contraindications include prostate cancer, breast cancer in males, severe untreated polycythemia (hematocrit >54% at baseline), and known hypersensitivity to testosterone or the cottonseed oil vehicle used in cypionate formulations. Relative contraindications include sleep apnea, severe benign prostatic hyperplasia with urinary obstruction, and severe hepatic impairment.

Dosing Protocols Used in Clinical Trials and Practice

The FDA-approved dosing for male hypogonadism with testosterone cypionate is 50 to 400 mg administered intramuscularly every 2 to 4 weeks. Clinical trials in HIV wasting have generally used the following regimens:

Standard Intramuscular Dosing

• 200 mg IM every 2 weeks: The most common dose in published HIV wasting trials. Produces testosterone peaks of approximately 900 to 1,100 ng/dL at 48 to 72 hours post-injection, with troughs often falling to 300 to 400 ng/dL just before the next dose.
• 100 mg IM weekly: Produces steadier serum levels with a peak-to-trough variation of roughly 30%, compared with 60 to 70% variation on the biweekly schedule. Many contemporary clinicians prefer this to reduce symptom fluctuation.

Subcutaneous Administration

Some prescribers use subcutaneous injection at 50 to 75 mg weekly. Absorption is slightly slower, producing a flatter concentration curve. No HIV wasting RCT has specifically studied the subcutaneous route, but pharmacokinetic data in hypogonadal populations suggest comparable bioavailability. pubmed.ncbi.nlm.nih.gov/17520786

Duration of Therapy

Published trials ran for 12 to 24 weeks. Lean body mass gains appear to plateau around 16 to 24 weeks if dose and resistance training load are held constant. Long-term therapy beyond 24 weeks is common in clinical practice for patients who respond, but evidence beyond 6 months in the HIV wasting population is limited.

Monitoring Requirements

Monitoring testosterone cypionate therapy in HIV-positive patients requires attention to the same parameters used in standard TRT, with additional HIV-specific considerations. The following framework reflects current endocrinology society guidance from the Endocrine Society (Bhasin S et al., JCEM 2018) applied to the HIV context.

Baseline Workup Before the First Dose

Every patient should have the following before injection number one:

• Total serum testosterone (two morning fasting measurements, at least 1 week apart)
• Complete blood count (CBC) including hematocrit and hemoglobin
• Comprehensive metabolic panel including liver function tests (AST, ALT, bilirubin, albumin)
• Fasting lipid panel (total cholesterol, LDL, HDL, triglycerides)
• PSA (prostate-specific antigen) in men over 40 or those with prostate risk factors
• CD4 count and HIV viral load (existing HIV monitoring; coordinate with infectious disease team)
• DEXA scan for body composition if available (quantifies lean mass and fat mass separately, providing a cleaner outcome measure than body weight alone)

Monitoring at 3 Months

Three months after starting therapy:

• Total testosterone (drawn at trough, i.e., just before the next scheduled injection) to confirm serum levels are in the 400 to 700 ng/dL range
• CBC with hematocrit (erythrocytosis risk; hold therapy if hematocrit exceeds 54%)
• PSA in men over 40

The Endocrine Society 2018 guideline states: "We suggest that clinicians check hematocrit at baseline and after 3 to 6 months, and then annually. If hematocrit is greater than 54%, stop therapy until hematocrit decreases to a safe level." pubmed.ncbi.nlm.nih.gov/29562364

Monitoring at 6 Months and Annually Thereafter

• Total testosterone (trough)
• CBC
• Fasting lipid panel (testosterone can reduce HDL cholesterol by 5 to 10%)
• LFTs (injectable testosterone has lower hepatotoxicity risk than oral 17-alpha-alkylated androgens, but liver monitoring remains standard practice)
• PSA annually in men over 40
• Body weight and subjective assessment of muscle strength
• DEXA scan at 6 to 12 months to document lean mass response objectively

HIV-Specific Monitoring Considerations

Patients on ART should have viral load and CD4 count monitored per their infectious disease provider's schedule, which is typically every 3 to 6 months. Testosterone does not appear to meaningfully alter ART pharmacokinetics at standard doses, but drug interaction checks are advisable when initiating any new therapy in a patient on a complex ART regimen. Protease inhibitors such as ritonavir can inhibit CYP3A4, which has minor relevance to testosterone's hepatic metabolism.

Adverse Effects and Risk Management

Erythrocytosis

The most clinically significant safety concern with intramuscular testosterone cypionate is erythrocytosis (elevated red blood cell mass). Rates of hematocrit exceeding 50% occur in approximately 5 to 10% of patients on standard doses. Hematocrit above 54% raises viscosity enough to increase thromboembolic risk. Management options include dose reduction, switching to a shorter-acting formulation, dose interval lengthening, or therapeutic phlebotomy in refractory cases.

Dyslipidemia

Testosterone replacement may reduce HDL cholesterol modestly, by 5 to 10% in most trials. In HIV-positive patients already at elevated cardiovascular risk due to chronic inflammation and some ART regimens, this warrants attention. Annual lipid monitoring and lifestyle counseling apply.

Testicular Atrophy and Fertility

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis, reducing endogenous testosterone production and spermatogenesis. Men who wish to preserve fertility should not use testosterone cypionate without concurrent gonadotropin support (e.g., human chorionic gonadotropin). Testicular atrophy may be partially reversible on discontinuation but recovery time varies.

Injection-Site Reactions

Testosterone cypionate is dissolved in cottonseed oil and may cause local inflammation at the injection site. Patients with cottonseed oil allergy should use an alternative carrier (sesame oil-based formulations exist). Technique training reduces the incidence of nodules and sterile abscesses.

Mood and Behavior

Supraphysiologic testosterone levels can cause irritability and mood instability in some patients. Keeping trough levels in the 400 to 700 ng/dL range rather than the 900 to 1,200 ng/dL range used in some older HIV trials reduces this risk.

Interaction with Modern ART Regimens

Most integrase strand-transfer inhibitor (INSTI)-based regimens (bictegravir/emtricitabine/tenofovir alafenamide, dolutegravir-based regimens) have minimal pharmacokinetic interaction with testosterone. Pharmacokinetic data specific to testosterone cypionate plus common modern ART regimens are limited, but theoretical risk is low given testosterone's relatively simple hepatic metabolism. Prescribers should consult a current drug interaction checker (e.g., the University of Liverpool HIV Drug Interaction Checker) and document the review in the chart.

Alternatives and Adjunctive Therapies

Nandrolone Decanoate

Nandrolone decanoate (an anabolic steroid with a more favorable androgenic-to-anabolic ratio) has also been studied in HIV wasting. A 1999 trial (N=24) showed comparable lean mass gains to testosterone but with less androgenic side effects. It is not a scheduled controlled substance in the same class in some jurisdictions, but it carries its own regulatory and monitoring considerations.

Megestrol Acetate

Megestrol acetate (Megace) is sometimes prescribed for appetite stimulation in HIV wasting. It stimulates appetite and fat gain but suppresses endogenous testosterone production, often worsening hypogonadism. Combining megestrol with testosterone has been studied; the combination maintains lean mass better than megestrol alone. pubmed.ncbi.nlm.nih.gov/10072128

Nutritional Optimization

No anabolic drug works well in the absence of adequate protein intake. A target of 1.2 to 1.6 grams of protein per kilogram of body weight per day is recommended alongside testosterone therapy, consistent with general guidance for muscle-preserving interventions in catabolic illness.

Resistance Training Protocol

All major trials showing lean mass gains from testosterone in HIV wasting included structured resistance training. Clinicians prescribing testosterone cypionate for this indication should provide or refer patients to a structured program of at least two to three resistance training sessions per week. The Bhasin 2000 trial used a supervised progressive resistance program three times weekly as the exercise component. pubmed.ncbi.nlm.nih.gov/10720063

Informed Consent: What Patients Must Know

Informed consent for off-label testosterone cypionate in HIV wasting should cover the following elements, ideally documented in a signed consent form:

1. The drug is not FDA-approved for this specific use.
2. Evidence comes primarily from small RCTs conducted before 2005; long-term safety data in this population are limited.
3. Schedule III controlled substance status and the legal requirements around prescribing.
4. The monitoring schedule (labs at 3 months, 6 months, then annually).
5. The specific risks: erythrocytosis, dyslipidemia, testicular atrophy, mood changes, injection-site reactions.
6. That stopping therapy may result in loss of the lean mass gained.

Patients who understand these points can make a genuinely informed choice. Skipping this conversation is not acceptable for off-label Schedule III prescribing.

Practical Prescribing Summary

For a 38-year-old HIV-positive male with documented weight loss of 12% from baseline and a total testosterone of 198 ng/dL on two morning measurements, a reasonable starting protocol after informed consent, baseline labs, and coordination with the infectious disease team would be testosterone cypionate 100 mg IM weekly. Recheck total testosterone at trough (just before the next injection) at week 12. If trough is below 350 ng/dL and hematocrit is below 50%, consider increasing to 150 mg weekly. If trough is above 700 ng/dL or hematocrit exceeds 50%, reduce the dose or extend the interval.

Schedule a DEXA scan at baseline and repeat at month 6. If lean mass has not increased by at least 1 kg at 6 months and the patient is adherent to the injection schedule and a structured resistance training program, the clinical team should reconsider whether testosterone cypionate is the appropriate primary intervention.